LIMINATUS PHARMA, INC.
(LIMN)Financial Statements · SEC EDGAR XBRL
Net Income
-$10.2M
-187.8%
EPS
$-0.43
-115.0%
Op. Income
-$3.0M
+10.9%
FCF
-$10.0M
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)